Immunic Therapeutics

NEWS

Multiple sclerosis damaged myelin or MS autoimmune disease with healthy nerve with exposed fibre with scarrred cell sheath loss as a 3D illustration.

Beyond BTK Inhibitors: Next Gen MS Treatments Could Transcend Symptom Management

While Bruton’s tyrosine kinase inhibitors are often hailed as the next big breakthrough in multiple sclerosis, Immunic Therapeutics and others are leveraging neuroprotective targets and remyelination to keep the disease at bay.

October 6, 2025

5 min read

Ben Hargreaves

IN THE PRESS

Press Releases

Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium

March 10, 2026

9 min read

Press Releases

Immunic to Participate in Investor Conferences in March 2026

March 3, 2026

5 min read

Press Releases

Immunic Announces Closing of Oversubscribed Private Placement Financing

February 18, 2026

7 min read

Press Releases

Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company

February 13, 2026

13 min read

Press Releases

Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis

February 4, 2026

11 min read

Press Releases

Immunic Highlights 2025 Accomplishments and Upcoming Milestones

January 7, 2026

12 min read

Press Releases

Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December

November 27, 2025

4 min read

Press Releases

Immunic to Participate in Industry and Investor Conferences in November 2025

October 29, 2025

4 min read

Press Releases

Immunic to Participate in Scientific and Investor Conferences in October 2025

October 1, 2025

7 min read

Press Releases

Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis

September 25, 2025

15 min read

JOBS